Recent News

• 08.05.2026 - ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
• 07.29.2026 - ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
• 05.06.2026 - ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
• 05.04.2026 - ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older
• 04.29.2026 - ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
• 03.27.2026 - ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
• 03.25.2026 - ADMA Biologics Addresses Misleading Short-Seller Report
• 03.02.2026 - ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
• 02.25.2026 - ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• 02.18.2026 - ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Recent Filings

• 08.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2026 - 8-K Current report
• 08.05.2026 - EX-99.1 EX-99.1
• 07.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.02.2026 - 8-K Current report
• 05.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.14.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]